A Phase 3 interventional study of Tirzepatide and Insulin Lispro (U100) in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 135 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-02.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 5 that started in 2020, is one of 17 in phase 3, and was the 18th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,428 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 14th largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2020, is one of 85 in phase 3, and was the 165th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
Drug: Tirzepatide
10 mg tirzepatide administered SC once a week.
Drug: Tirzepatide
15 mg tirzepatide administered SC once a week.
Drug: Tirzepatide
Insulin lispro 100 units per milliliter (U100) administered SC three times a day.
Drug: Insulin Lispro (U100)
Administered SC
Also known as: LY3298176
Administered SC
Also known as: LY275585
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 52
Change From Baseline in HbA1c
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 52
Percentage of Participants With HbA1c Target Values <7.0%
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Week 52
Change From Baseline in Body Weight
LS mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 52
Change From Baseline in Fasting Serum Glucose
LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 52
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 52
Percentage of Participants Who Achieved HbA1c Target Value of <7.0% Without Hypoglycemia
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Week 52
Percentage of Participants Who Achieved Weight Loss ≥5%
Percentage of Participants who Achieved Weight Loss ≥5% is reported here.
Time frame: Week 52
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. PCS score is reported here. PCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by analysis of covariance (ANCOVA) model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).
Time frame: Baseline, Week 52
Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. MCS score is reported here. MCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by ANCOVA model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).
Time frame: Baseline, Week 52
| Milestone | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Started | 243 | 238 | 236 | 711 |
| Received at least one dose of study drug | 243 | 238 | 236 | 708 |
| Completed | 228 | 228 | 225 | 623 |
| Not completed | 15 | 10 | 11 | 88 |
| Withdrew: Adverse event | 2 | 1 | 2 | 4 |
| Withdrew: Death | 3 | 3 | 1 | 11 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 6 |
| Withdrew: Physician decision | 1 | 0 | 2 | 5 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 4 | 4 | 58 |
| Withdrew: Missed study visits | 2 | 0 | 0 | 3 |
| Withdrew: Sponsor's decision | 0 | 0 | 1 | 1 |
| Withdrew: Safety reasons | 1 | 0 | 0 | 0 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percentage of HbA1c | Pooled 5 mg/10 mg/15 mg Tirzepatide | Insulin Lispro |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) | -2.26 ± 0.048 | -1.16 ± 0.049 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percentage of HbA1c | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Change From Baseline in HbA1c | -2.05 ± 0.082 | -2.27 ± 0.083 | -2.46 ± 0.084 | -1.16 ± 0.049 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Percentage of Participants With HbA1c Target Values <7.0% | 61.04 | 75.64 | 79.86 | 36.69 |
LS mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Kilograms (kg) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -6.9 ± 0.37 | -9.9 ± 0.37 | -12.0 ± 0.38 | 3.8 ± 0.22 |
LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| milligram per Deciliter (mg/dL) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose | -33.2 ± 3.28 | -43.0 ± 3.32 | -41.6 ± 3.42 | -10.0 ± 1.99 |
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was determined by MMRM model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| mg/dL/day | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values | -56.7 ± 1.80 | -61.5 ± 1.85 | 67.6 ± 1.86 | -55.8 ± 1.13 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c Target Value of <7.0% Without Hypoglycemia | 52.70 | 70.05 | 75.12 | 13.41 |
Percentage of Participants who Achieved Weight Loss ≥5% is reported here.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss ≥5% | 64.19 | 79.21 | 83.15 | 6.34 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. PCS score is reported here. PCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by analysis of covariance (ANCOVA) model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).
| score on a scale | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score | 1.0 ± 0.46 | 1.7 ± 0.46 | 1.7 ± 0.48 | -0.6 ± 0.28 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. MCS score is reported here. MCS domain is scored by summing individual items and transforming scores into a 0 to 100 scale with higher scores indicating better health status or functioning. LS mean was determined by ANCOVA model with variables Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).
| score on a scale | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score | 0.3 ± 0.59 | 1.5 ± 0.59 | 0.7 ± 0.62 | -1.3 ± 0.36 |
Collected over Baseline up to week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide | 3/243 (1.2%) | 20/243 (8.2%) | 94/243 (38.7%) |
| 10 mg Tirzepatide | 3/238 (1.3%) | 16/238 (6.7%) | 116/238 (48.7%) |
| 15 mg Tirzepatide | 1/236 (0.4%) | 17/236 (7.2%) | 121/236 (51.3%) |
| Insulin Lispro | 11/708 (1.6%) | 81/708 (11.4%) | 99/708 (14%) |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 2/243 | 3/238 | 1/236 | 28/708 |
| Covid-19Infections and infestations | 1/243 | 1/238 | 2/236 | 7/708 |
| Covid-19 pneumoniaInfections and infestations | 2/243 | 2/238 | 2/236 | 7/708 |
| PneumoniaInfections and infestations | 1/243 | 1/238 | 2/236 | 0/708 |
| Ischaemic strokeNervous system disorders | 0/243 | 1/238 | 2/236 | 1/708 |
| Acute myocardial infarctionCardiac disorders | 0/243 | 2/238 | 0/236 | 2/708 |
| ErysipelasInfections and infestations | 2/243 | 0/238 | 0/236 | 0/708 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/144 | 0/149 | 0/133 | 0/396 |
| Acute coronary syndromeCardiac disorders | 0/243 | 0/238 | 1/236 | 0/708 |
| Angina unstableCardiac disorders | 0/243 | 0/238 | 1/236 | 3/708 |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 33/243 | 49/238 | 61/236 | 8/708 |
| Decreased appetiteMetabolism and nutrition disorders | 20/243 | 28/238 | 40/236 | 1/708 |
| DiarrhoeaGastrointestinal disorders | 29/243 | 36/238 | 26/236 | 17/708 |
| VomitingGastrointestinal disorders | 11/243 | 21/238 | 30/236 | 4/708 |
| Covid-19Infections and infestations | 28/243 | 19/238 | 21/236 | 72/708 |
| DyspepsiaGastrointestinal disorders | 15/243 | 27/238 | 27/236 | 4/708 |
| ConstipationGastrointestinal disorders | 6/243 | 8/238 | 14/236 | 4/708 |
All randomized participants.
| Age, Continuous(years) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro | Total |
|---|---|---|---|---|---|
| Mean | 58.00 ± 10.18 | 59.60 ± 9.41 | 58.20 ± 9.62 | 59.00 ± 9.74 | 58.80 ± 9.75 |
| Sex: Female, Male(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro | Total |
|---|---|---|---|---|---|
| Female | 144 | 149 | 133 | 398 | 824 |
| Male | 99 | 89 | 103 | 313 | 604 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 148 | 142 | 149 | 446 | 885 |
| Not Hispanic or Latino | 95 | 93 | 87 | 261 | 536 |
| Unknown or Not Reported | 0 | 3 | 0 | 4 | 7 |
| Race (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 2 | 3 |
| Asian | 2 | 0 | 2 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 11 | 9 | 11 | 26 | 57 |
| White | 230 | 224 | 220 | 671 | 1345 |
| More than one race | 0 | 5 | 2 | 8 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro | Total |
|---|---|---|---|---|---|
| Argentina | 70 | 70 | 70 | 207 | 417 |
| Belgium | 0 | 1 | 0 | 1 | 2 |
| Brazil | 47 | 47 | 46 | 141 | 281 |
| Czechia | 10 | 9 | 9 | 29 | 57 |
| Germany | 7 | 8 | 8 | 24 | 47 |
| Greece | 2 | 2 | 2 | 9 | 15 |
| Hungary | 4 | 4 | 2 | 9 | 19 |
| Italy | 1 | 2 | 1 | 2 | 6 |
| Mexico | 19 | 20 | 20 | 59 | 118 |
| Romania | 14 | 14 | 12 | 38 | 78 |
| Russia | 19 | 17 | 19 | 52 | 107 |
| Slovakia | 16 | 13 | 15 | 39 | 83 |
| Spain | 5 | 3 | 3 | 14 | 25 |
| Turkey | 1 | 0 | 1 | 2 | 4 |
| United States | 28 | 28 | 28 | 85 | 169 |
| Hemoglobin A1c(Percentage of HbA1c) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Insulin Lispro | Total |
|---|---|---|---|---|---|
| Mean | 8.89 ± 0.97 | 8.78 ± 0.98 | 8.74 ± 1.01 | 8.81 ± 0.96 | 8.80 ± 0.97 |
Showing the first 100 of 135 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2020 to primary completion in Oct 2022, 23 months.
Results were first posted in Nov 2023, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide